SGR 1505
Alternative Names: SGR-1505Latest Information Update: 28 Nov 2025
At a glance
- Originator Schrodinger
- Class Antineoplastics; Small molecules
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
Yes - Mantle-cell lymphoma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I B-cell lymphoma
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for phase-I development in B-cell lymphoma(Combination therapy, Late-stage disease, Second-line therapy or greater) in Moldova (PO)
- 28 Nov 2025 No recent reports of development identified for phase-I development in B-cell lymphoma(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)
- 28 Nov 2025 No recent reports of development identified for phase-I development in B-cell lymphoma(Late-stage disease, Monotherapy, Second-line therapy or greater) in Moldova (PO)